What is past is prologue: estrogen/progestin replacement tomorrow

References

• European Institute of Women's Health. Gender Mainstreaming in EU Public Health. Dublin: Euro-pean Institute of Women's Health, 2000:1–10
   Google Scholar
• Purdie DW. Consequences of long-term hor-mone replacement therapy. Br Med Bull 2000;56: 809–23
   Google Scholar
• Tsang TSM, Barnes ME, Gersh BJ, Hayes SN. Risks of coronary heart disease in women: current understanding and evolving concepts. Mayo Clin Proc 2000;75:1289–303
   Google Scholar
• Pilon D, Castilloux A-M, Lelorier J. Estrogen replacement therapy: determinants of persistence with treatment. Obstet Gynecol 2001;97:97–100
   Google Scholar
• Shackelford DP, Lalikos JF. Estrogen replace-ment therapy and the surgeon. Am J Surg 2000; 179:333–6
   Google Scholar
• Brett KM, Makans JH. Use of postmenopausal hormone replacement. Am J Epidemiol 1997;145: 536–45
   PubMed Web of Science ®Google Scholar
• Siiteri PK, MacDonald PC. Role of extra-glandular estrogens in human endocrinology. In Geiger SR, Astwood EB, Greep RO, eds. Hand-book of Physiology, vol 2. Bethesda, MD: American Physiological Society, 1973:615–29
   Google Scholar
• Judd HL, Shamonki IM, Frumar AM, Lagasse LD. Origin of serum estradiol in postmenopausal women. Obstet Gynecol 1982;59:680–6
   PubMed Web of Science ®Google Scholar
• Lauritzen C. History of estrogen research. In Oettel M, Schillinger E, eds. Handbook of Experi-mental Pharmacology, vol 135/I, Estrogens and Anti-estrogens I. Berlin: Springer, 1999:1–14
   Google Scholar
• Inhoffen HH, Hohlweg W. Neue per os wirksame weibliche Keimdriisenhormon-derivate: 17-Aethinyl-oestradiol und Pregnen-in-on-3-01-17. Naturwissenschaften 1938;26: 96–101
   Google Scholar
• Allen WM, Corner GW. Physiology of corpus luteum. VII. Maintenance of pregnancy in rabbit after very early castration, by corpus luteum extracts. Proc Soc Exp Biol (NY) 1930;27: 403–10
   Google Scholar
• Clauberg C. Zur Physiologie und Pathologie der Sexualhormone, im besonderen des Hormons des Corpus luteum. I. Mitt. Der biologische Test fir das Luteohormon am infantilen Kaninchen. Zbl Gynäkol 1930;54:2757–61
   Google Scholar
• Butenandt A, Westphal U, Hohlweg W. Ober das Hormon des Corpus luteum. Physiol Chem 1934;227:84–90
   Google Scholar
• Allen WM, Wintersteiner 0. Crystalline pro gestin. Science 1934;80: 190–4
   Google Scholar
• Slotta KH, Ruschig H, Fels E. Reindarstellung der Hormone aus dem Corpus luteum. Ber Dtsch Chem Ges 1934;67:1270–5
   Google Scholar
• Hartmann M, Wettstein A. EM kristallisiertes Hormon aus Corpus luteum. Hely Chim Acta 1934;17:878–82
   Google Scholar
• Andersson K, Mattson LO, Rybo G, Stadberg E. Intrauterine release oflevonorgestrel — a new way of adding progesto gen on hormone replacement therapy. Obstet Gynecol 1992;79:963–7
   PubMed Web of Science ®Google Scholar
• Luukkainen T. The levonorgestrel intrauterine system: therapeutic aspects. Steroids 2000;65: 699–702
   PubMed Web of Science ®Google Scholar
• Nilsson CG, Haukkamaa M, Vierola H, Luukkainen T. Tissue concentrations oflevo nor-gestrel in women using levonorgestrel-releasing IUD. Clin Endocrinol 1982;17:529–36
   PubMed Web of Science ®Google Scholar
• Nilsson CG, Luukkainen T, Arko H. Endo-metrial morphology of women using a d-norgestrel-releasing intrauterine device. Fertil Steril 1978;29:397–401
   Google Scholar
• Lähteennijki P, Rauramo I, Backman T. The levonorgestrel intrauterine system in contracep-tion. Steroids 2000;65:693–7
   Google Scholar
• Raudaskoski TH, Lahti El, Kauppila AJ, Apaja-Sarkkinen MA, Laatikainen TJ. Transderrnal estrogen with a levonorgestrel-releasing intra-uterine device for climacteric complaints: clinical and endometrial responses. Am J Obstet Gynecol 1995;172:114–19
   Google Scholar
• Suhonen S, Allonen H, Lähteenmäki P. Sustained-release estradiol implants and a levonorgestrel-releasing intrauterine device in hormone replacement therapy. Am J Obstet Gynecol 1995;172:562–7
   Google Scholar
• Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin 1996;65:5–27
   Web of Science ®Google Scholar
• Messina MJ, Persky V, Setchell KDR, Barnes S. Soy intake and cancer risk: a review of the in vitro and in vivo data. Nutr Cancer 1994;21:113–31
   PubMed Web of Science ®Google Scholar
• Tamura Y, Hirai A, Terano T, Yoshida S. Clini-cal and epidemiological studies of-3 polyunsat-urated fatty acids in Japan. In Tanaka T, Okada A, eds. Nutritional Support in Organ Failure. New York: Excerpta Medica,1990:89–95
   Google Scholar
• Barnes S. Effect of genistein on in vitro and in vivo models of cancer. J Nutr 1995;125:777–835
   PubMed Web of Science ®Google Scholar
• Ho SC, Woo JLF, Leung SSF, Sham ALK, Lam TH, Janus ED. Intake ofsoy products is associated with better plasma lipid profiles in the Hong Kong Chinese population. J Nutr 2000;130: 2590–3
   PubMed Web of Science ®Google Scholar
• Somekawa Y, Chiguchi M, Ishibashi T, Aso T. Soy intake related to menopausal symptoms, serum lipids, and bone mineral density in postmenopausal Japanese women. Obstet Gynecol 2001;97:109–15
   PubMed Web of Science ®Google Scholar
• Nakagawa H, Yamamoto D, Kiyozuka Y, et al. Effects of genistein and synergistic action in com-bination with eicosapentaenoic acid on the growth ofbreast cancer cell lines .J Cancer Res Clin Oncol 2000;126:448–54
   PubMed Web of Science ®Google Scholar
• Mazur W, Adlercreutz H. Overview of naturally occurring endocrine-active substances in the human diet in relation to human health. Nutrition 2000;16:654–87
   PubMed Web of Science ®Google Scholar
• Nikov GI, Hopkins NE, Boue S, Alwort WL. Interactions of dietary estrogens with human estrogen receptors and the effect of estrogen receptor—estrogen response element complex formation. Environ Health Perspect 2000;108: 867–72
   PubMed Web of Science ®Google Scholar
• Dubey RK, Gillespie DG, Imthurn B, Rosselli M, Jackson EK, Keller PJ. Phytoestrogens inhibit growth and MAP kinase activity in human aortic smooth muscle cells. Hypertension 1999;33: 177–82
   PubMed Web of Science ®Google Scholar
• Wiseman H. The therapeutic potential of phyto-estrogens . Exp Opin Invest Drugs 2000;9:1829–40
   PubMed Web of Science ®Google Scholar
• Burger HG. Selective oestrogen receptor modu-lators. Horm Res 2000;53(Suppl 3):25–9
   Google Scholar
• Johnston CC and the Raloxifene Study Group. Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women. Arch Intern Med 2000;160:3444–50
   Google Scholar
• Clemett D, Spencer CM. Raloxifene — a review of its use in postmenopausal osteoporosis. Drugs 2000;60:379–411
   PubMed Web of Science ®Google Scholar
• Yang NN, Venugopalan M, Hardikar S. Identifi-cation of an estrogen response element activated by metabolites of 17-beta-estradiol and raloxi-fene. Science 1996;273: 1222–5
   Google Scholar
• Nuttall ME, Stroup GB, Fisher PW, Nadeau DP, Gowen M, Suva IT Distinct mechanisms of action of selective estrogen receptor modulators in breast and osteoblastic cells. Am J Physiol Cell Physiol 2000;279:C1550–7
   Google Scholar
• Gize EA, Venugopalan M, Glasebrook AL. Characterization of raloxifene binding and trans-activation properties of the estrogen receptor-beta (ERI3) (abstr S428). J Bone Miner Res 1997;Supp112:S460
   Google Scholar
• Dutertre M, Smith CL. Molecular mechanisms of selective estrogen receptor modulator (SERM) action. J Pharmacol Exp Ther 2000;295:431–7
   PubMed Web of Science ®Google Scholar
• Katzenellenbogen BS, Choi I, Delage-Mourroux R, et al. Molecular mechanisms of estrogen action: selective ligands and receptor pharmaco-logy. J Steroid Biochem Mol Biol 2000;74:279–85
   Google Scholar
• Dardes RC, Jordan VC. Novel agents to modu-late oestrogen action. Br Med Bull 2000;56: 773–86
   Google Scholar
• Osborne CK, Zhao HH, Fuqua SAW. Selective estrogen receptor modulators: structure, func-tion, and clinical use. J Clin Oncol 2000;18: 3172–86
   Google Scholar
• Levenson AS, Catherino WH, Jordan VG. Estro-genic activity is increased for an antiestrogen by a natural mutation of the estrogen recepto r.J Steroid Biochem Mol Biol 1997;60:261–8
   Google Scholar
• Cyr M, Calon F, Morisette M, Grandbois M, Callier S, DiPaolo T. Drugs with estrogen-like potency and brain activity: potential therapeutic applications for the CNS. Curr Pharm Design 2000;6:1287–312
   PubMed Web of Science ®Google Scholar
• Verghese J, Kuslansky G, Katz MJ, et al. Cog-nitive performance in surgically menopausal women on estrogen. Neurology 2000;55:872–4
   PubMed Web of Science ®Google Scholar
• Jones KP. Menopause and cognitive function: estrogens and alternative therapies. Clin Obstet Gynecol 2000;43:198–206
   Google Scholar
• Hogervorst E, Williams J, Budge M, Riedel W, Jones J. The nature of the effect of female gonadal hormone replacement therapy on cognitive func-tion in postmenopausal women: a meta-analysis. Neuroscience 2000;101:485–512
   Google Scholar
• Paganini-Hill A, Henderson VW. Estrogen defi-ciency and risk of Alzheimer's disease in women. Am J Epidemiol 1994;140:256–63
   Google Scholar
• Leranth C, Roth RH, Elswoth JD, Naftolin F, Horvath TL, Redmond DE. Estrogen is essential for maintaining nigostrial dopamine neurons in primates: implications for Parkinson's disease and memory. J Neurosci 2000;20:8604–9
   PubMed Web of Science ®Google Scholar
• Green PS, Yang S-H, Nilsson KR, Kumar AS, Covey DF, Simpkins JW. The nonfeminizing enantiomer of 1713-estradiol exerts protective effects in neuronal cultures and a rat model of cerebral ischemia. Endocrinology 2001;142: 400–6
   Google Scholar
• Neuwinger J, Esper J, Miick I, Wildt L. Biologi-cal effects of 17a-estradiol in hypogonadal women. Acta Endocrinol 1992;126(Suppl 4):83
   Google Scholar
• Berlau J, Roemer W, Oettel M, Hipler UC, Patchev V, Schreiber G. 17a-oestradiol and 17I3-o estradiol do not affect basal and follicle-stimulating hormone-stimulated inhibin B secre-tion by highly purified rat Sertoli cells. Andrologia 2000;32:345–9
   Google Scholar
• Schröder J, Dören M, Schneider B, Oettel M. Are the antioxidative effects of 1713-estradiol modified by concomitant administration of a progestin? Maturitas 1996;25:133–9
   PubMed Web of Science ®Google Scholar
• Römer W, Oettel M, Droescher P, Schwarz S. Novel `scavestrogens' and their radical scavenging effects, iron-chelating, and total antioxidative activities: A"-dehydro derivatives of 17a-estradiol and 1713-estradiol. Steroids 1997;62: 304–10
   Google Scholar
• Oettel M, Römer W, Heller R. The therapeutic potential of scavestrogens. Eur J Obstet Gynecol 1996;65:1253
   Google Scholar
• Blum-Degen D, Haas M, Pohli S, et al. Scavestrogens protect IMR 32 cells from oxida-tive stress-induced cell death. Toxicol Appl Pharmacol 1998;152: 49–55
   Google Scholar
• Götz ME, Ahlbom E, Zhivotovsky B, et al. Radical scavenging compound J 811 inhibits hydrogen peroxide-induced death of cerebellar granule cells. J Neurosci Res 1999;56: 420–6
   Google Scholar
• Blum-Degen D, Götz ME. Novel 17a-estradiol analogues as potent radical scavengers. In Iqbal K, Swaab DF, Winblad B, Wisniewski HM, eds. Alzheimer's Disease and Related Disorders. New York: John Wiley & Sons, 1999
   Google Scholar
• Dare E, Götz ME, Zhivotovsky B, Manzo L, Ceccatelli S. Antioxidants J 811 and 1713-estradiol protect cerebellar granule cells from methyl-mercury-induced apoptotic cell death. J Neurosci Res 2000;62:557–65
   PubMedGoogle Scholar
• Buko V, Lukivskaya 0, Naruta E, et al. Radical-scavenging and antiatherogenic effects of scav-estrogens in cholesterol-fed rabbits. Fund Clin Pharmacol 1999;13(Suppl 1):PM 167
   Google Scholar
• Zhi L, Tegley CM, Edwards JP, et al. 5-Alkyl 1,2-dihydrochromenoll3,4-fiquinolines: a novel class of nonsteroidal progesterone receptor modulators. Bioorg Med Chem Left 1998;8: 3365–70
   Google Scholar
• Meda C, Vegeto E, Pollio G, et al. Oestrogen pre-vention of neuronal cell death correlates with decreased expression of mRNAQ for the pro-ap optotic protein Nip-2.J Neuroendocrinol 2000; 12:1051–9
   Google Scholar
• Patchev V, Römer W, Schwarz S, et al. Non-feminizing radical-scavenging estrogens: evi-dence for selective neurotropic action in vivo and implications in neuroprotection. Xth International Congress on Hormonal Steroids, Quebec City, June 17–21,1998:198
   Google Scholar
• Oettel M. Estrogens and antiestrogens in the male. In Oettel M, Schillinger E, eds. Handbook of Experimental Pharmacology, vol 135/II, Estrogens and Antiestrogens II. Berlin: Springer-Verlag, 1999:505–71
   Google Scholar
• Simpson ER, Davis SR. Another role highlighted for estrogens in the male: sexual behavior. Proc Nat Acad Sci 2000;97:14038–40
   Google Scholar
• Van den Beld AW, Lamberts SWJ. The male climacterium: clinical signs and symptoms of a changing endocrine environment. Prostate 2000; 10(Suppl):2–8
   Google Scholar
• Järvinen A, Nyldnen S, Paasiniemi L. Absorption and bioavailability of oestradiol from a gel, a patch and a tablet. Maturitas 1999;32:103–13
   Google Scholar
• Scott RT, Ross B, Anderson C, Archer DF. Pharmacokinetics of percutaneous estradiol: a crossover study using a gel and a transdermal system in comparison with oral micronized estradiol. Obstet Gynecol 1991;77:758–64
   PubMed Web of Science ®Google Scholar
• Simon JA, Hodgen GD, Archer DF. Are there any significant pharmacokinetic differences between patch and gel cutaneous estradiol therapy? In Genazzani AR, Petraglia F, Volpe A, Fachinetti F, eds. Recent Research on Gynecological Endocrinology, vol 2. Camforth, UK: Parthenon Publishing, 1988:317–24
   Google Scholar
• Scott RT, Ross B, Anderson C, Archer DF. Pharmacokinetics of percutaneous estradiol: a crossover study using a gel and a transdermal system in comparison with oral micronized estradiol. Obstet Gynecol 1991;77:758–64
   PubMed Web of Science ®Google Scholar
• Järvinen A, Nyldnen S, Paasiniemi L. Absorption and bioavailability of oestradiol from a gel, a patch and a tablet. Maturitas 1999;32:103–13
   Google Scholar
• Hoibraaten E, Qvigstad E, Arnesen H, Larsen S, Wickstrom E, Sandset PM. Increased risk of recurrent venous thromboembolism during hor-mone replacement therapy. Thromb Haemost 2000;84:961–7
   PubMed Web of Science ®Google Scholar
• Schwarz S, Weber G, Kiihner F. Sulfamate des 17aAthinylestradiols. Z Chem 1970;10: 299–300
   Google Scholar
• Stölzner W. Tierexperimenteller Beitrag zur Entwicklung estrogener Wirkstoffe. Dissertation (Promotion B), Friedrich-Schiller Universität Jena, 1989
   Google Scholar
• Elger W, Schwarz S, Hedden A, Reddersen G, Schneider B. Sulfamates of various estrogens are pro drugs with increased systemic and reduced hepatic estrogenicity at oral application. J Steroid Biochem Mol Biol 1995;55:395–403
   Google Scholar
• Schwarz S, Elger W. Estrogen sulfamates, a novel approach to oral contraception and hormone replacement therapy. Drugs Future 1996 ;21:49–61
   Google Scholar
• Elger W, Palme HJ, Schwarz S. Novel oestrogen sulfamates: a new approach to oral hormone therapy. Exp Opin Invest Drugs 1998;7:575–89
   Google Scholar
• Lippert TH, Seeger H, Möck AO. The impact of endogenous estradiol metabolites on carcino-genesis. Steroids 2000;65:357–69
   Google Scholar
• Clemons M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med 2001;344:276–85
   PubMed Web of Science ®Google Scholar
• Singh A, Purohit A, Hejaz HAM, Potter BVL, Reed MJ. Inhibition of deoxyglucose uptake in MCF-7 breast cancer cells by 2-methoxyestrone and 2-methoxyestrone-3-0-sulfamate. Mol Cell Endocrinol 2000;160: 61–6
   Google Scholar
• MacCarthy-Morrogh L, Townsed PA, Purohit A, et al. Differential effects of estrone and estrone-3-0-sulfamate derivatives on mitotic arrest, apoptosis, and microtubule assembly in human breast cancer cells. Cancer Res 2000;60: 5441–50
   Google Scholar
• Purohit A, Dauvois S, Parker MG, Potter BVL, Williams GJ, Reed MJ. The hydrolysis of oestrone sulphate and dehydroepiandrosterone sulphate by human steroid sulphatase expressed in transfected COS-1 cells. J Steroid Biochem Mol Biol 1994;50:101–4
   PubMedGoogle Scholar
• Howarth NM, Purohit A, Reed MJ, Potter BVL. Estrone sulfamates: potent inhibitors of estrone sulfatase with therapeutic potential. J Med Chem 1994;37:219–21
   PubMed Web of Science ®Google Scholar
• Purohit A, Williams GJ, Howarth NM, Potter BVL, Reed MJ. Inactivation of steroid sulfatase by an active site-directed inhibitor, estrone-3-0-sulfamate. Biochemistry 1995;34: 11508–14
   Google Scholar
• Purohit A, Williams GJ, Roberts CJ, Potter BVL, Reed MJ. In vivo inhibition ofo estrone sulphatase and dehydroepiandrosterone sulphatase by o es tro ne-3-0-sulphamate . Int J Cancer 1995;63: 106–11
   Google Scholar
• Reed MJ, Purohit A, Duncan LJ, et al. The role of cytokines and sulphatase inhibitors in regulating oestrogen synthesis in breast tumours. J Steroid Biochem Mol Biol 1995;53:413–20
   PubMedGoogle Scholar
• Loo LWL, Lightowler M, Purohit A, Reed MJ, Potter BVL. Heteroatom-substituted analogues of the active-site directed inhibitor estra-1,3,5 (10)-trien-17-one-3-sulphamate inhibit estrone sulphatase by a different mechanism. J Steroid Biochem Mol Biol 1996;57: 79–88
   Google Scholar
• Selcer KW, Jagannathan S, Rhodes ME, Li PK. Inhibition of placental estrone sulfatase activity and MCF-7 breast cancer cell proliferation by estrone-3-amino derivatives. J Steroid Biochem Mol Bio/ 1996;59:83–91
   PubMed Web of Science ®Google Scholar
• Purohit A, Froome VA, Wang DY, Potter BVL, Reed MJ. Measurement of oestrone sulphatase activity in white blood cells to monitor in vivo inhibition of steroid sulphatase activity by o estrone-3-0-sulphamate. J Steroid Biochem Mol Biol 1997;62: 45–51
   Google Scholar
• Howarth NM, Purohit A, Reed MJ, Potter BVL. Estrone sulfonates as inhibitors of estrone sulfatase. Steroids 1997;62:346–50
   PubMed Web of Science ®Google Scholar
• Woo LWL, Howarth NM, Purohit A, Hejaz HAM, Reed MJ, Potter BVL. Steroidal and nonsteroidal sulfamates as potent inhibitors of steroid sulfatase. J Med Chem 1998;41:1068–83
   PubMed Web of Science ®Google Scholar
• Römer W, Oettel M, Schwarz S. Scavestrogen sulfamates: correlation between estrone sulfatase inhibiting and antioxidant effects. Can J Physiol Pharmacol 1998;76:99–109
   Google Scholar
• Ciobanu LC, Boivin RP, Van Luu-The, Labrie F, Poirier D. Potent inhibition of steroid sulfatase activity by 3-0-sulfamate 17a-benzyl (or 4'-tert-butylbenzyl) estra-1,3,5(10)-trienes: com-bination of two substituents at positions C3 and C17a of estradiol. J Med Chem 1999;42: 2280–6
   Google Scholar
• Hejaz HAM, Purohit A, Mahon MF, Reed MJ, Potter BVL. Synthesis and biological activity of thesup eres tro gen(E) -17-o ximino-3-0-sulfamoy1-1,3,5(10)-estratriene: X-ray crystal structure of (E)-17-oximino-3-hydroxy-1,3,5 (10)-etratriene. J Med Chem 1999;42: 3188–92
   Google Scholar
• Valigora SD, Li KP, Dunphy G, Turner M, Ely DL. Steroid sulfatase inhibitor alters blood pressure and steroid profiles in hypertensive rats. J Steroid Biochem Mol Biol 2000;73:113–22
   PubMed Web of Science ®Google Scholar
• Barth A, Römer W, Oettel M. Influence of sub chronic administration of oestrone-3-0-sulphamate on oestrone sulphatase activity in liver, spleen and white blood cells of ovari-ectomized rats. Arch Toxicol 2000;74:366–71
   Google Scholar
• Li PK, Rhodes ME, Jagannathan S, Johnson DA. Reversal of scopolamine induced amnesia in rats by the steroid sulfatase inhibitor estrone-3-0-sulfamate. Cogn Brain Res 1995;2:251–4
   PubMedGoogle Scholar
• Flood JF, Farr SA, Johnson DA, Li PK, Morley JE. Peripheral steroid sulfatase inhibition poten-tiates improvement of memory retention for hippocampally administered dehydroepiandro-sterone sulfate but not pregnenolone sulfate. Psychoneuroendocrinology 1999;24:799–811
   Google Scholar
• Nedvidkova J, Haluzik M, Pacak K, Schreiber V, Starka L. Estrogenic effects of estradiol-sulfamate on the male rat anterior pituitary. J Steroid Biochem Mol Biol 1998;67:359–62
   Google Scholar
• Aragones MIH, Purohit A, Parish D, Sahm UG. Pouton CW, Potter BVL, Reed MJ. Pharma-cokinetics of oestrone-3-0-sulphamate.J Steroid Biochem Mol Biol 1996;58: 611–17
   Google Scholar
• Zimmermann H, Elger W, Oettel M. Compara-tive toxicology ofethinylestradiol (EE) and a new estrogen without 17-alpha ethinyl group: 17-beta-estradio1-3-sulfamate (J 995). Toxicol Lett 1996;88(Suppl):100
   Google Scholar
• Barth A, Elger W, Schneider B, Schwarz S. Influ-ence of subchronic administration of oestradiol, ethinyloestradiol and oestradiol sulphamate on bile flow, bile acid excretion, and liver and biliary glutathione status in rats. Arch Toxicol 1997;71: 443–9
   Google Scholar
• Elger W, Palme HJ, Schwarz S. Novel oestrogen sulfamates: a new approach to oral hormone therapy. Exp Opin Invest Drugs 1998;7:575–89
   Google Scholar
• Hoffmann H, Moore C, Zimmermann H, et al. Approaches to the replacement of ethinylestradiol by natura11713-estradiol in combined oral contra-ceptives. Exp Toxic Pathol 1998;50:458–64
   PubMed Web of Science ®Google Scholar
• Gruber DM, Wieser F, Sator M, Gruber JC. Die Bedeutung des Progesterons und der Gestagene im Klimakterium. Zbl Gynäkol 1997;119:34–7
   Google Scholar
• Kuhl H. Comparative pharmacology of newer progestogens. Drugs 1996;51:188–215
   PubMed Web of Science ®Google Scholar
• Sitruk-Ware R. Progestins and cardiovascular risk markers. Steroids 2000;65:651–8
   PubMed Web of Science ®Google Scholar
• Campagnoli C, Belforte P, DiSario MM, Lesca L. Lipid profile during hormone replacement therapy: effect of different progestins? Zbl Gynäkol 1997;119:1–6
   Google Scholar
• Oettel M, Holz C. Hybrid progestins: the example of dienogest. In Sitruk-Ware R, Mishell DR, eds. Proges tins and Antiprogestins in Clinical Practice. New York: Marcel Dekker, 2000: 163–78
   Google Scholar
• Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000;62:29–38
   PubMed Web of Science ®Google Scholar
• Philibert D, Bouchoux F, Degryse M, Lecaque D, Petit F, Gaillard M. The pharmacological pro-file of a novel norpregnane progestin (trimeges-tone). Gynecol Endocrinol 1999;13:316–26
   PubMed Web of Science ®Google Scholar
• Sorbera LA, Leeson PA, Castaner J. Trime-gestone. Drugs Future 2000;25:465–73
   Google Scholar
• Paris JM, Williams KJ, Hermsmeyer KR, Delansorne R. Nomegestrol acetate and vascular reactivity: nonhuman primate experiments. Steroids 2000;65:621–7
   PubMedGoogle Scholar
• Kumar N, Koide SS, Tsong Y-Y, Sundaram K. Nestorone®: a progestin with a unique pharma-cological profile. Steroids 2000;65:629–36
   Google Scholar
• Oettel M, Graeser T, Hoffmann H, Moore C, Zimmermann H, Zimmermann T. The preclini-cal profile of dienogest. A short overview. Drugs Today 1999;35(Suppl C):3–12
   Google Scholar
• Katsuki Y, Hirano K. Mechanism of action of dienogest, a synthetic steroid. Gffu Yakka Daigaku Kiyo 1999;48:33–42
   Google Scholar
• Oettel M, Bervoas-Martin S, Elger W, et al. A 19-norprogestin without 17a-ethinyl group I: dienogest from a pharmacokinetic point of view. Drugs Today 1995;31:499–516
   Google Scholar
• Oettel M, Carol W, Elger W, et al. A 19-norprogestin without 17a-ethinyl group II: dienogest from a pharmacodynamic point of view. Drugs Today 1995;31:517–36
   Google Scholar
• Schneider B, Elger W, Ernst M. Assessment of gestagen effects on bone metabolism in the rat. Exp Clin Endocrinol 1993;101 (Suppl 1):71
   Google Scholar
• Shibutani Y, Futamura Y, Katsuki Y. Bone-resorptive cytokine inhibitor containing dieno-gest as the active ingredient. European Patent Application EP 1 043 331 Al, 2000
   Google Scholar
• HaywoodL, Kasperk CH, Wakley GK. Progestin and androgen co-therapy prevents loss of can-cellous bone mass after ovarian hormone deple-tion. 2001;in press
   Google Scholar
• Oettel M, Bo cker T, Giittner J, Horn M, Stölzner W. Studie zur Entwicklung eines geeigneten Modells zur Endometriosis externa bei Kaninchen und Ratten und die Effekte von Dienogest und Danazol. Fertilität 1992;8:134–5
   Google Scholar
• Moore C, Carol W, Gräser T, Mellinger U, Walter F. Influence of dienogest on ovulation in young fertile women. Clin Drug Invest 1999;18: 271–8
   Web of Science ®Google Scholar
• Katsuki Y, Takano Y, Futamura Y, et al. Effects of dienogest, a synthetic steroid, on experimental endometriosis in rats. Eur J Endocrinol 1998;138: 216–26
   PubMed Web of Science ®Google Scholar
• Gräser T, Muller A, Mellinger U, Muck AO, Lippert TH, Oettel M. Continuous-combined treatment of the menopause with combinations of oestradiol valerate and dienogest — a dose-ranging study. Maturitas 2000;35:253–61
   Google Scholar
• Hammarbäck S, Bäckström T, Hoist J, von Schoultz B, Lyrends S. Cyclical mood changes as in the premenstrual tension syndrome during sequential estrogen—progestogen postenopausal replacement therapy. Acta Obstet Gynecol Scand 1985;64:393–7
   PubMed Web of Science ®Google Scholar
• Magos AL, Brewster E, Sing R, O'Dowd TM, Studd JWW. The effect of norethisterone in postmenopausal women on oestrogen therapy: a model for the premenstrual syndrome. BrJ Obstet Gynaecol 1986;93:1290–6
   Google Scholar
• Panay N, Studd J. Progestogen intolerance and compliance with hormone replacement therapy in menopausal women. Hum Reprod Update 1997;3:159–71
   PubMed Web of Science ®Google Scholar
• Björn I, Bixo M, Strandberg K, Nyberg S, Bäckström T. Negative mood changes during hormone replacement therapy: a comparison between two progestogens. Am J Obstet Gynecol 2000;183:1419–26
   Google Scholar
• Zweifel JE, O'Brian WH. A meta-analysis of the effect of hormone replacement therapy upon depressed mood. Psychoneuroendocrinology 1997; 22:189–212
   PubMed Web of Science ®Google Scholar
• Sherwin BB. The impact of different doses of estrogen and progestin on mood and sexual behaviour in postmenopausal women. J Clin Endocrinol Metab 1991;72:336–43
   PubMed Web of Science ®Google Scholar
• Persson I. Estrogens in the causation of breast, endometrial and ovarian cancers — evidence and hypotheses from epidemiological findings. J Steroid Biochem Mol Biol 2000;74:357–64
   PubMed Web of Science ®Google Scholar
• Santen RJ, Pinkerton J, McCartney C, Petroni GR. Risk of breast cancer with progestins in combination with estrogen as hormone replace-ment therapy. J Clin Endocrinol Metab 2001;86: 16–23
   PubMed Web of Science ®Google Scholar
• Katsuki Y, Shibutani Y, Aoki D, Nozawa S. Dienogest, a novel synthetic steroid, overcomes hormone-dependent cancer in a different manner than progestins . Cancer 1997;79:169–76
   PubMed Web of Science ®Google Scholar
• Futamara Y, Nakamura M. Neovascularization inhibitor containing dienogest as the active ingre-dient. European Patent Application EP 1 048 673 Al, 2000
   Google Scholar
• Ishikawa T, Inoue S, Kakinuma C, Kuwayama C, Hamada Y, Shibutani Y. Growth-stimulating effect of dienogest, a synthetic steroid, on rodent, canine, and primate mammary glands. Toxicology 2000;151:91–101
   Google Scholar
• Kam GYW, Leung K-C, Baxter RC, Ho KKY. Estrogens exert route- and dose-dependent effects on insulin-like growth factor (IGF)-binding protein-3 and the acid-labile subunit of the IGF ternary complex. J Clin End ocrinol Metab 2000;85: 1918–22
   Google Scholar
• Cardim HJP, Lopes CMC, Giannella-Neto D, da Fonseca AM, Pinozzi JA. The insulin-like growth factor-I system and hormonal replacement therapy. Fertil Steril 2001;75:282–7
   Google Scholar
• Gräser T, Koytchev R, Milner A, Oettel M. Comparison of the efficacy and endometrial safety of two estradiol valerate/dienogest combi-nations and Kliogest® for continuous combined hormone replacement therapy in postmenopausal women. Climacteric 2000;3:109–18
   Google Scholar
• Campagnoli C, Biglia N, Lanza MG, Lesca L, Pens C, Sismondi P. Androgenic progestogens oppose the the decrease of insulin-like growth factor I serum level induced by conjugated oestrogens in postmenopausal women. Prelimi-nary report. Maturitas 1994;19:25–31
   PubMed Web of Science ®Google Scholar
• Hankinson SE, Willett WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor I and risk of breast cancer. Lancet 1998; 351:1393–6
   PubMed Web of Science ®Google Scholar
• Byrne C, Colditz GA, Willett WC, Speizer FE, Pollak M, Hankinson SE. Plasma insulin-like growth factor (IGF) I, IGF-bindingprotein 3, and mammographic density. Cancer Res 2000;60: 3744–8
   PubMed Web of Science ®Google Scholar
• Coelingh Bennink HJT. The Jerusalem declara-tion on progesterone receptor modulators. Steroids 2000;65:839
   Google Scholar
• Mulac-Jericevic B, Mullinax RA, DeMayo FJ, Lydon JP, Conneely OM. Subgroup of repro-ductive functions of progesterone mediated by progesterone receptor-B isoform. Science 2000; 289:1751–4
   Google Scholar
• Conneely OM, Lydon JP. Progesterone receptors in reproduction: functional impact of the A and B isoforms. Steroids 2000;65:571–7
   PubMed Web of Science ®Google Scholar
• Hirata S, Shoda T, Kato J, Hoshi K. The novel isoform of the progesterone receptor cDNA in the human testis and detection of its rn_RNA in the human uterine endometrium. Oncology 2000; 59(Suppl 1):39–44
   Google Scholar
• Kloosterboer HJ, Deckers GH, Schoonen WGEJ, et al. Preclinical experience with two selective progesterone receptor modulators on breast and endometrium. Steroids 2000;65: 733–40
   PubMed Web of Science ®Google Scholar
• Klijn JGM, Setyono-HanB, Foekens JA. Proges-terone antagonists and progesterone modulators in the treatment ofbreast cancer. Steroids 2000;65: 825–30
   PubMed Web of Science ®Google Scholar
• Wagner BL, Polio G, Giangrande P, et al. The novel progesterone antagonists RTI 3021-012 and RTI 3021-022 exhibit complex gluco-corticoid receptor antagonist activities: implica-tions for the development of dissociated antiprogestins. Endocrinology 1999;140:1449–58
   PubMed Web of Science ®Google Scholar
• Jones TK, Pathirana C, Goldman ME, et al. Dis-covery of novel intracellular receptor modulating drugs.J Steroid Biochem Mol Biol 1996;56:61–6
   Google Scholar
• Edwards JP, Zhi L, Pooley CLF, et al. Prepara-tion, resolution, and biological evaluation of 5-aryl-1,2-dihydro-5H-chromeno [3,4-f]quino - lines: potent, orally active, nonsteroidal proges-terone receptor agonists. J Med Chem 1998;41: 2779–85
   Google Scholar
• Dukes M, Furr BJA, Hughes LR, Tucker H, Woodburn JR. Nonsteroidal progestins and anti-progestins related to flutamide. Steroids 2000;65: 725–31
   Google Scholar
• Elger W, Bartley J, Schneider B, Kaufmann G, Schubert G, Chwalisz K. Endocrine pharmaco-logical characterization of progesterone antago-nists and progesterone receptor modulators with respect to PR-agonistic and antagonistic activity. Steroids 2000;65:713–23
   PubMed Web of Science ®Google Scholar
• Chwalisz K, Brenner RM, Fuhrmann U, Hess-Stumpf H, Elger W. Antiproliferative effects of progesterone antagonists and progesterone recep-tor modulators on the endometrium. Steroids 2000;65:741–51
   Google Scholar
• Elger W, Chwalisz K. Antigestagene fiir die gyrijkologische Therapie. Reproduktionsmedizin 1999;15:318–35
   Google Scholar
• Arlt W, Justl HG, Callies F, et al. Oral dehydro-epiandrosterone for adrenal androgen replace- ment:pharmaco kineticsandperipheralconversion to androgens and estrogens in young healthy females after dexamethas one suppression. J Clin Endocrinol Metab 1998;83:1928–34
   PubMed Web of Science ®Google Scholar
• Arlt W, Haas J, Callies F, et al. Bio transformation of oral dehydroepiandrosterone in elderly men: significant increase in circulating estrogens. J Clin Endocrinol Metab 1999;84:2170–6
   PubMed Web of Science ®Google Scholar
• Callies F, Arlt W, Siekmann L, Hiibler D, Bidlingmaier F, Allolio B. Influence of oral dehydroepiandrosterone (DHEA) on urinary steroid metabolites in males and females. Steroids 2000;65:98–102
   Google Scholar
• Arlt W, Callies F, Van Vlijmen JC, et al. Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Engl J Med 1999; 341:1013–20
   PubMed Web of Science ®Google Scholar
• Allolio B, Arlt W. Dehydroepiandrosterone sub-stitution in women. J Endocrinol Invest 1999;22 (Suppl 10) :29–31
   Google Scholar
• Negro-Vilar A. Selective androgen receptor modulators (SARM's): a novel approach to androgen therapy for the new millennium.J Clin Endocrinol 1999;84:3459–62
   PubMed Web of Science ®Google Scholar
• Miiller JM, Isele U, Metzger E, et al. FHL2, a novel tissue-specific coactivator of the androgen receptor (AR). EMBO J 2000;19:359–69
   Google Scholar